A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

Author： Camidge D.   Smethurst Dominic   Growcott Jim   Barrass Nigel   Foster John   Febbraro Salvatore   Swaisland Helen   Hughes Andrew  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.60, Iss.3, 2007-08, pp. : 391-398

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

By Camidge D.   Pemberton Mike   Growcott Jim   Amakye Dereck   Wilson David   Swaisland Helen   Forder Cheryl   Wilkinson Robert   Byth Kate   Hughes Andrew  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 4, 2007-09 ,pp. : 479-488

Springer Publishing Company

Access to resources Recommend Favorite

First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers

By Saito Kaku   Nagashima Hirotaka   Noguchi Kazuharu   Yoshisue Kunihiro   Yokogawa Tatsushi   Matsushima Eiji   Tahara Takeshi   Takagi Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 577-583

Springer Publishing Company

Access to resources Recommend Favorite

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

By Dickson Mark   Shah Manish   Rathkopf Dana   Tse Archie   Carvajal Richard   Wu Nian   Lefkowitz Robert   Gonen Mithat   Cane Lauren   Dials Heather   Schwartz Gary  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1113-1121

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

Expression and Subcellular Localization of the Cyclin-Dependent Kinase Inhibitor p27 Kip1 in Epithelial Ovarian Cancer

By Hurteau J.A.   Allison B.M.   Brutkiewicz S.A.   Goebl M.G.   Heilman D.K.   Bigsby R.M.   Harrington M.A.  

Gynecologic Oncology, Vol. 83, Iss. 2, 2001-11 ,pp. : 292-298

Elsevier

Access to resources Recommend Favorite